Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention

Molecular Pharmaceutics

Volumn 2, Issue 5, 2005, Pages 373-383

  Sahoo, Sanjeeb K ^a   Labhasetwar, Vinod ^a,b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer therapy; Drug resistance; Exocytosis and endocytosis; Intracellular uptake and sorting; Sustained action

Indexed keywords

EPOXIDE; LIGAND; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; POLYMER; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL LEVEL; CELL STRAIN MCF 7; COMPARATIVE STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RETENTION; DRUG UPTAKE; ENCAPSULATION; ENDOCYTOSIS; EXOCYTOSIS; HUMAN; HUMAN CELL; INCUBATION TIME; MOLECULAR MECHANICS; PRIORITY JOURNAL;

CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTRACELLULAR SPACE; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR STRUCTURE; NANOSTRUCTURES; TAXOIDS; TEMPERATURE; TRANSFERRIN;

EID: 24144490885     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp050032z     Document Type: Article

References (48)

1. Andrews, N. C. Iron homeostasis: insights from genetics and animal models. Nat. Rev. Genet. 2000, 1, 208-217.
2. Qian, Z. M.; Tang, P. L. Mechanisms of iron uptake by mammalian cells. Biochim. Biophys. Acta 1995, 1269, 205-214.
3. Qian, Z. M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 54, 561-587.
4. Widera, A.; Norouziyan, F.; Shen, W. C. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv. Drug Deliv. Rev. 2003, 55, 1439-1466.
5. Li, H.; Qian, Z. M. Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 2002, 22, 225-250.
6. Li, H.; Sun, H.; Qian, Z. M. The role of the transferrin-transferrin- receptor system in drug delivery and targeting. Trends Pharmacol. Sci. 2002, 23, 206-209.
7. Pardridge, W. M. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv. Exp. Med. Biol. 2002, 513, 397-430.
8. Bickel, U.; Yoshikawa, T.; Pardridge, W. M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 2001, 46, 247-279.
9. Wang, F.; Jiang, X.; Yang, D. C.; Elliott, R. L.; Head, J. F. Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res. 2000, 20, 799-808.
10. Lemieux, P.; Page, M. Sensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate. Anticancer Res. 1994, 14, 397-403.
11. Endicott, J. A.; Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 1989, 58, 137-171.
12. Flens, M. J.; Izquierdo, M. A.; Scheffer, G. L.; Fritz, J. M.; Meijer, C. J.; Scheper, R. J.; Zaman, G. J. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994, 54, 4557-4563.
13. Langer, R. Drug delivery and targeting. Nature 1998, 392, 5-10.
14. Maruyama, K.; Ishida, O.; Takizawa, T.; Moribe, K. Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Deliv. Rev. 1999, 40, 89-102.
15. Vyas, S. P.; Singh, A.; Sihorkar, V. Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. Crit. Rev. Ther. Drug Carrier Syst. 2001, 18, 1-76.
16. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2002, 54, 631-651.
17. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55, 329-347.
18. Sahoo, S. K.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discovery Today 2003, 8, 1112-1120.
19. Panyam, J.; Zhou, W. Z.; Prabha, S.; Sahoo, S. K.; Labhasetwar, V. Rapid endo-lysosomal escape of poly(D,L-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002, 16, 1217-1226.
20. Panyam, J.; Labhasetwar, V. Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res. 2003, 20, 212-220.
21. Panyam, J.; Sahoo, S. K.; Prabha, S.; Bargar, T.; Labhasetwar, V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int. J. Pharm. 2003, 262, 1-11.
22. Desai, M. P.; Labhasetwar, V.; Walter, E.; Levy, R. J.; Amidon, G. L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 1997, 14, 1568-1573.
23. Prabha, S.; Labhasetwar, V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol. Pharm. 2004, 1, 211-219.
24. Sahoo, S. K.; Ma, W.; Labhasetwar, V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 2004, 112, 335-340.
25. Sahoo, S. K.; Panyam, J.; Prabha, S.; Labhasetwar, V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Controlled Release 2002, 82, 105-114.
26. Shuai, X.; Merdan, T.; Schaper, A. K.; Xi, F.; Kissel, T. Core-cross-linked polymeric micelles as paclitaxel carriers. Bioconjugate Chem. 2004, 15, 441-448.
27. Prabha, S.; Zhou, W. Z.; Panyam, J.; Labhasetwar, V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int. J. Pharm. 2002, 244, 105-115.
28. Panyam, J.; Williams, D.; Dash, A.; Leslie-Pelecky, D.; Labhasetwar, V. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J. Pharm. Sci. 2004, 93, 1804-1814.
29. Mu, L.; Feng, S. S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J. Controlled Release 2002, 80, 129-144.
30. Qaddoumi, M. G.; Ueda, H.; Yang, J.; Davda, J.; Labhasetwar, V.; Lee, V. H. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm. Res. 2004, 21, 641-648.
31. Mao, H. Q.; Roy, K.; Troung-Le, V. L.; Janes, K. A.; Lin, K. Y.; Wang, Y.; August, J. T.; Leong, K. W. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Controlled Release 2001, 70, 399-421.
32. Ravi Kumar, M.; Hellermann, G.; Lockey, R. F.; Mohapatra, S. S. Nanoparticle-mediated gene delivery: state of the art. Expert Opin. Biol. Ther. 2004, 4, 1213-1224.
33. Panyam, J.; Labhasetwar, V. Targeting intracellular targets. Curr. Drug Delivery 2004, 1, 235-247.
34. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4, 253-265.
35. Kavanagh, C. A.; Rochev, Y. A.; Gallagher, W. M.; Dawson, K. A.; Keenan, A. K. Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems. Pharmacol. Ther. 2004, 102, 1-15.
36. Jang, S. H.; Wientjes, M. G.; Lu, D.; Au, J. L. Drug delivery and transport to solid tumors. Pharm. Res. 2003, 20, 1337-1350.
37. Panyam, J.; Labhasetwar, V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol. Pharm. 2004, 1, 77-84.
38. Ballare, C.; Portela, P.; Schiaffi, J.; Yomha, R.; Mordoh, J. Reactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15. Breast Cancer Res. Treat. 1998, 47, 163-170.
39. Singh, M.; Atwal, H.; Micetich, R. Transferrin directed delivery of adriamycin to human cells. Anticancer Res. 1998, 18, 1423-1427.
40. Fritzer, M.; Szekeres, T.; Szuts, V.; Jarayam, H. N.; Goldenberg, H. Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells. Biochem. Pharmacol. 1996, 51, 489-493.
41. Lopes, N. M.; Adams, E. G.; Pitts, T. W.; Bhuyan, B. K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 1993, 32, 235-242.
42. Ruthner, M.; Berczi, A.; Goldenberg, H. Interaction of a doxorubicin-transferrin conjugate with isolated transferrin receptors. Life Sci. 1994, 54, 35-40.
43. Berczi, A.; Ruthner, M.; Szuts, V.; Fritzer, M.; Schweinzer, E.; Goldenberg, H. Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. Eur. J. Biochem. 1993, 213, 427-436.
44. St'astny, M.; Strohalm, J.; Plocova, D.; Ulbrich, K.; Rihova, B. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur. J. Cancer 1999, 35, 459-466.
45. Huwyler, J.; Cerletti, A.; Fricker, G.; Eberle, A. N.; Drewe, J. By-passing of P-glycoprotein using immunoliposomes. J. Drug Targeting 2002, 10, 73-79.
46. Joshee, N.; Bastola, D. R.; Cheng, P. W. Transferrin-facilitated lipofection gene delivery strategy: characterization of the transfection complexes and intracellular trafficking. Hum. Gene Ther. 2002, 13, 1991-2004.
47. Cheng, P. W. Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin. Hum. Gene Ther. 1996, 7, 275-282.
48. Sato, Y.; Yamauchi, N.; Takahashi, M.; Sasaki, K.; Fukaura, J.; Neda, H.; Fujii, S.; Hirayama, M.; Itoh, Y.; Koshita, Y.; Kogawa, K.; Kato, J.; Sakamaki, S.; Niitsu, Y. In vivo gene delivery to tumor cells by transferrin- streptavidin-DNA conjugate. FASEB J. 2000, 14, 2108-2118.